The most commonly observed adverse events (AEs) in the phase III trials were dose-dependent anemia and thrombocytopenia, which were anticipated as thrombopoietin and erythropoietin signal through JAK2[11]. The gene discussed is THPO; the disease is Thrombocytopenia.